BidaskClub Upgrades TG Therapeutics (TGTX) to “Hold”

TG Therapeutics (NASDAQ:TGTX) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

A number of other equities research analysts have also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a research note on Tuesday, January 16th. Zacks Investment Research raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 16th. Raymond James reissued a “buy” rating on shares of TG Therapeutics in a research note on Thursday, April 19th. B. Riley reissued a “buy” rating and issued a $27.00 price target (up previously from $21.50) on shares of TG Therapeutics in a research note on Friday, March 9th. Finally, ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $24.60.

TG Therapeutics opened at $14.05 on Wednesday, MarketBeat.com reports. The company has a market cap of $1.04 billion, a PE ratio of -7.36 and a beta of 1.21. TG Therapeutics has a 1-year low of $13.48 and a 1-year high of $13.80.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.15). TG Therapeutics had a negative net margin of 87,025.00% and a negative return on equity of 170.83%. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. sell-side analysts anticipate that TG Therapeutics will post -1.99 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in the stock. venBio Select Advisor LLC boosted its stake in TG Therapeutics by 58.7% during the 1st quarter. venBio Select Advisor LLC now owns 5,229,619 shares of the biopharmaceutical company’s stock worth $74,261,000 after purchasing an additional 1,935,156 shares during the last quarter. BlackRock Inc. boosted its stake in TG Therapeutics by 1.8% during the 1st quarter. BlackRock Inc. now owns 3,475,206 shares of the biopharmaceutical company’s stock worth $49,348,000 after purchasing an additional 60,207 shares during the last quarter. Franklin Resources Inc. boosted its stake in TG Therapeutics by 3.7% during the 4th quarter. Franklin Resources Inc. now owns 2,457,415 shares of the biopharmaceutical company’s stock worth $20,151,000 after purchasing an additional 87,398 shares during the last quarter. Senzar Asset Management LLC boosted its stake in TG Therapeutics by 56.9% during the 4th quarter. Senzar Asset Management LLC now owns 1,355,178 shares of the biopharmaceutical company’s stock worth $11,112,000 after purchasing an additional 491,678 shares during the last quarter. Finally, Columbus Circle Investors boosted its stake in TG Therapeutics by 39.6% during the 1st quarter. Columbus Circle Investors now owns 761,030 shares of the biopharmaceutical company’s stock worth $10,807,000 after purchasing an additional 215,976 shares during the last quarter. 47.35% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply